Germany-based Fresenius Kabi, a leading name in healthcare, has struck an accord with Ori Biotech Ltd, a London-headquartered cell and gene therapy (CGT) manufacturing technology leader. The partnership aims to integrate the IRO platform with Fresenius Kabi’s Cue and Lovo Cell Processing Systems, marking a significant step in the advancement of upstream and downstream processing technologies in CGT.
Integration of IRO Platform and Processing Systems
The integration of the IRO platform with Fresenius Kabi’s Cue and Lovo Cell Processing Systems is expected to provide a new modular CGT GMP manufacturing solution. This integration will streamline process steps, minimize tube and bag transfers, and reduce operator contact time, leading to a closed, end-to-end workflow. The combined system promises to offer maximum flexibility and scalability while ensuring product quality and consistency, which are crucial for the success of CGT therapies.
Advantages of the New Modular Solution
The new modular CGT GMP manufacturing solution will address the challenges of traditional manufacturing processes by reducing complexity and increasing efficiency. The integration of IRO with LOVO and CUE processing systems will not only enhance the manufacturing process but also contribute to the development of more effective and safer cell and gene therapies.-Fineline Info & Tech
